Amy Waterman
Primary Care · Sheldon, IANPI 1104335496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $210 and has fallen 61.2% since, to $81 in 2025.
Across 38 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$122
- Amgen$78
- Mylan Specialty L.p.$74
- Lilly USA, LLC$66
- Pfizer$58
- Bayer$54
- plus $154 from 8 others
What the payments were for
- Food & beverage$605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $122 |
| Amgen | 5 | $78 |
| Mylan Specialty L.p. | 4 | $74 |
| Lilly USA, LLC | 4 | $66 |
| Pfizer | 3 | $58 |
| Bayer | 4 | $54 |
| Novo Nordisk | 3 | $41 |
| Exact Sciences | 1 | $19 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Medtronic | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$605 in reported general payments places this provider in the 65th percentile of 36 primary care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $75,719 |
| OzempicSemaglutide | 56 | $58,459 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $29,126 |
| MounjaroTirzepatide | 16 | $17,726 |
| XareltoRivaroxaban | 28 | $17,274 |
| Spiriva RespimatTiotropium Bromide | 12 | $16,379 |
| JardianceEmpagliflozin | 19 | $12,094 |
| FarxigaDapagliflozin Propanediol | 17 | $12,048 |
| EntrestoSacubitril/Valsartan | 15 | $11,410 |
| MyrbetriqMirabegron | 17 | $8,956 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,181 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 18 | $5,279 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,079 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 12 | $2,549 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $75,719137 claims |
| Novo NordiskOzempic | $41 | $58,45956 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $12 | $28,47331 claims |
| Lilly USA, LLCMounjaro | $66 | $17,72616 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $8,95617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 36 primary care providers in Iowa.
Other primary care in Sheldon
- Emily WickhamCouncil Bluffs$7K
- Erin SwailesHiawatha$4K
- Jessica OgdenNewton$2K
- Jody HorstmanWest Des Moines$2K
- Chimene CobbLenox$2K
- Mary PedersenJefferson$1K
- Jamie HicksMilford$847
- Jennifer BlaylockAnkeny$787
- Catherine VailCouncil Bluffs$748
- Jennifer HutchinsonWest Union$664
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.